IMVT logo

IMMUNOVANT INC

IMVTNASDAQ
🏆 #1082 by market capUS Equity
$33.49▲ $0.03 (+0.09%)
Market closed · at close
🔔
Track IMVT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.1%
7d▼ 3.1%
14d▼ 8.0%
30d▼ 18.0%
ytd▲ 31.8%
1y▲ 107.5%
🏦Market Cap
$6.91B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
64
Fair

Trading Snapshot

Day Range
$32.98 – $33.67
52-Week Range
$15.56 – $45.42
Volume
$6.10B
Avg Volume
$6.92B
Shares Outstanding
206.4M
Next Earnings
Dec 10, 2026

Fundamentals Snapshot

Annual Revenue
$922M
Last Q Revenue
$247M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-2.81
Dividend Yield
—

Why Investors Own IMVT

  • ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 78% gross margin and 23% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IMVT logo

IMMUNOVANT INC

IMVT
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$922M▲ +21.2% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
77.8%▲ +0.0% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$257M▲ +21.2% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$211M▲ +21.2% YoY
StockOtter · stockotter.space

About IMMUNOVANT INC

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$38.50
▲ +15.0% Upside
High Target$48.16
Low Target$29.21
Based on 26 analysts

Latest News & Updates

🚀
CNBC·2h ago

IMMUNOVANT INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift IMVT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

IMMUNOVANT INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.